Cd-Ga-102
Advanced Hepatocellular Carcinoma
Shanghai Changzheng Hospitalnucleic_acidEarly Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
37 Active assets in the Advanced Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Penpulimab West China Hospital | Phase 3 | BB |
Octreotide Pamoate Clinica Universidad de Navarra, Universidad de Navarra | Phase 3 | BB |
Dfn-15 Emory University | Phase 4 | BB |
Shr-8068 Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | B |
Serplulimab Shanghai Henlius Biotech | Phase 3 | B |
View all 50 →
Same molecule, other indications
Cd-Ga-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →